LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock. Issue 9 (18th September 2019)

• Record Type: Journal Article
• Authors: Guirgis, Faheem W; Black, Lauren Page; Rosenthal, Martin Daniel; Henson, Morgan; Ferreira, Jason; Leeuwenburgh, Christiaan; Kalynych, Colleen; Moldawer, Lyle L; Miller, Taylor; Jones, Lisa; Crandall, Marie; Reddy, Srinivasa T; Wu, Samuel S; Moore, Frederick A
• Is Part Of: BMJ open. Volume 9:Issue 9(2019)
• Publication Date: 2019-09-18
• Subjects: sepsis -- lipids -- lipid emulsion -- cholesterol -- organ failure -- parenteral nutrition; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-029348
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Sepsis is a life-threatening, dysregulated response to infection. Both high-density lipoprotein and low-density lipoprotein cholesterol should protect against sepsis by several mechanisms; however, for partially unknown reasons, cholesterol levels become critically low in patients with early sepsis who experience poor outcomes. An anti-inflammatory lipid injectable emulsion containing fish oil is approved by the Food and Drug Administration as parenteral nutrition for critically ill patients and may prevent this decrease in serum cholesterol levels by providing substrate for cholesterol synthesis and may favourably modulate inflammation. This LIPid Intensive Drug therapy for Sepsis Pilot clinical trial is the first study to attempt to stabilise early cholesterol levels using lipid emulsion as a treatment modality for sepsis. Methods and analysis: This is a two-centre, phase I/II clinical trial. Phase I is a non-randomised dose-escalation study using a Bayesian optimal interval design in which up to 16 patients will be enrolled to evaluate the safest and most efficacious dose for stabilising cholesterol levels. Based on phase I results, the two best doses will be used to randomise 48 patients to either lipid injectable emulsion or active control (no treatment). Twenty-four patients will be randomised to one of two doses of the study drug, while 24 control group patients will receive no drug and will be followed during their hospitalisation. The control group will receive all standard treatments mandated by the institutional sepsis alert protocol. The phase II study will employ a permuted blocked randomisation technique, and the primary endpoint will be change in serum total cholesterol level (48 hours − enrolment). Secondary endpoints include change in cholesterol level from enrolment to 7 days, change in Sequential Organ Failure Assessment score over the first 48 hours and 7 days, in-hospital and 28-day mortality, lipid oxidation status, inflammatory biomarkers, and high-density lipoprotein function. Ethics and dissemination: Investigators are trained and follow good clinical practices, and each phase of the study was reviewed and approved by the institutional review boards of each institution. Results of each phase will be disseminated through presentations at national meetings and publication in peer-reviewed journals. If promising, data from the pilot study will be used for a larger, multicentre, phase II clinical trial. Trial registration number: NCT03405870 .